The lack of distractions from a large domestic market and a close proximity of research centers are just two advantages for the flourishing Swiss biotech sector, which enjoyed a bumper year in 2021, says its industry association. 

AstraZeneca licenses bispecific cancer antibody candidate from Harbour Biomed. Regeneron seeks new approach to gene therapy delivery in deal with ViGeneron.

Private Company Edition: More $100m-plus mega-rounds means another billion-dollar week for venture capital deals, including financings for G2 Bio, Hummingbird and Numab. Also, BioTheryX brings in $92m, Vedere launches with $77m and Eliem raises $60m two months after launching with $80m. 

Swiss biotech Numab Therapeutics has raised an oversubscribed series C financing of CHF100m to accelerate the development of its multispecific antibodies, from investors attracted by the company’s thoughtful approach to developing its technology.